Laboratory Corporation of America Holdings ($LH) Stock Forecast: Up 5.8% Today

What is Laboratory Corporation of America Holdings?

Labcorp Holdings (LH) is a leading independent clinical laboratory in the U.S., offering a wide range of clinical lab tests. The stock had a strong bullish movement today.

Why is Laboratory Corporation of America Holdings going up?

LH stock is up 5.8% on Feb 18, 2026 15:16

• Labcorp's target price was raised to $326 by Baird, maintaining an "Outperform" rating, reflecting positive sentiment.
• Labcorp reported strong Q4 and full-year 2025 earnings, with an optimistic 2026 outlook driven by strategic priorities and upbeat profit forecasts.
• JPMorgan adjusted Labcorp's price target to $330, maintaining an "Overweight" rating, following the company's positive Q4 results and 2026 guidance.
• The bullish movement could be attributed to the company's strong financial performance, positive analyst ratings, and strategic growth initiatives, including the launch of an FDA-cleared Alzheimer's blood test.

LH Price Chart

LH Technical Analysis

LH News

Labcorp Hldgs (LH) Target Price Raised by Baird to $326 | LH Sto

Baird has raised its target price for Labcorp Holdings (LH) to $326 from $313, while maintaining an "Outperform" rating, indicating continued positive sentiment. This adjustment follows several other analysts who have also adjusted their ratings and price targets for Labcorp in recent months. Labcorp, one of the largest independent clinical laboratories in the U.S., offers a wide range of clinical lab tests.

https://www.gurufocus.com/news/8627503/labcorp-hldgs-lh-target-price-raised-by-baird-to-326-lh-stock-news

Labcorp Holdings Inc. (NYSE:LH) Q4 2025 Earnings Call Transcript

Labcorp Holdings Inc. (NYSE:LH) reported its Q4 and full-year 2025 earnings, announcing strong growth with over 7% top-line growth and 13% adjusted EPS growth for the year. The company provided an optimistic outlook for 2026, projecting approximately 9% adjusted EPS growth at the midpoint of its guidance, driven by strategic priorities such as deepening partnerships with health systems, advancing leadership in specialty testing, and leveraging technology and AI-powered solutions. Labcorp also addressed the delay of PAMA implementation and discussed its capital allocation strategy, including acquisitions and shareholder returns.

https://www.insidermonkey.com/blog/labcorp-holdings-inc-nyselh-q4-2025-earnings-call-transcript-1698109/

JPMorgan Adjusts Price Target on Labcorp Holdings to $330 From $319, Maintains Overweight Rating

JPMorgan has raised its price target for Labcorp Holdings (NYSE:LH) to $330 from $319, while maintaining an "Overweight" rating on the stock. This adjustment comes shortly after Labcorp reported its Q4 2025 results and provided guidance for 2026, which included upbeat annual profit forecasts driven by strong diagnostic product demand. The company also announced its Q4 adjusted earnings and revenue increases, alongside the launch of an FDA-cleared Alzheimer's blood test.

https://www.marketscreener.com/news/jpmorgan-adjusts-price-target-on-labcorp-holdings-to-330-from-319-maintains-overweight-rating-ce7e5ddedd8df527

DNA RNA Banking Services Market Is Going to Boom | Thermo Fisher Scientific • Illumina • 23andMe • AncestryDNA

This report by Coherent Market Insights analyzes the DNA RNA Banking Services Market, predicting substantial growth from 2026 to 2033 due to rising demand and innovation. It covers key market trends, drivers, competitive landscape, and strategic opportunities for industry leaders, identifying major players like Thermo Fisher Scientific and Illumina. The study utilizes analytical tools like SWOT analysis and Porter's Five Forces to provide comprehensive insights and forecasts for various segments and regions.

https://www.openpr.com/news/4395323/dna-rna-banking-services-market-is-going-to-boom-thermo-fisher

Labcorp Holdings Inc. (NYSE:LH) Given Average Recommendation of "Moderate Buy" by Brokerages

Labcorp Holdings Inc. (NYSE:LH) has received a consensus "Moderate Buy" rating from thirteen brokerages, with an average one-year price objective of $300.75. The company recently reported Q4 adjusted EPS that beat estimates, along with positive FY2026 guidance, though revenue missed expectations and insider selling occurred. Despite some negative sentiment regarding revenue and insider activity, institutional investors have shown increased interest, and the stock exhibits solid financial performance metrics.

https://www.marketbeat.com/instant-alerts/labcorp-holdings-inc-nyselh-given-average-recommendation-of-moderate-buy-by-brokerages-2026-02-18/

Trending Today

Bitcoin ($BTC) Crypto Forecast: Up 6.1% Today

Ethereum ($ETH) Crypto Forecast: Up 7.8% Today

Duolingo Inc. ($DUOL) Stock Forecast: Down 5.4% Today

Xerox Corporation ($XRX) Stock Forecast: Up 5.9% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.2% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Up 5.6% Today

Sonos Inc. ($SONO) Stock Forecast: Up 5.3% Today

Royal Caribbean Cruises Ltd. ($RCL) Stock Forecast: Down 5.3% Today

Roku Inc. ($ROKU) Stock Forecast: Up 5.0% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.5% Today

Laboratory Corporation of America Holdings Price History

14.02.2024 - LH Stock was down 2.9%

• The appointment of Bryan Riggsbee to CareDx's Board of Directors brings financial expertise and experience from other companies, potentially signaling a strategic advantage for CareDx over LabCorp.
• The insider selling of shares by Mark Schroeder, EVP and President Diagnostics & COO of LabCorp, may have raised concerns among investors about the company's future performance.
• The research report on the Europe Medical Diagnostics Market, including competitive analysis of LabCorp, Quest Diagnostics, and others, could have highlighted potential challenges or increased competition for LabCorp, impacting its stock performance negatively.
• Overall, these factors combined might have contributed to the bearish movement of LabCorp's stock today.

27.05.2023 - LH Stock was down 1.0%

• LH had a strong bearish movement today.
• The article suggests that the predictability of LH's cash flows is less visible, which may have contributed to the market movement.
• The article also mentions that LH's return on capital employed has lagged behind the required rate of return in the last two periods, which could be another factor affecting the stock's performance.

25.03.2024 - LH Stock was down 3.7%

• Labcorp reported its first-quarter results, showing an increase in profit that missed estimates, leading to a decline in its shares despite exceeding earnings expectations.
• The company revised its adjusted earnings and revenue growth guidance range for the fiscal year 2024, potentially disappointing investors.
• Despite a strong first-quarter performance, Labcorp faced high market expectations, resulting in a bearish trend in its stock price.
• The adjustment of the full-year guidance range and missing analyst estimates likely contributed to the negative market sentiment towards Labcorp today.

29.03.2024 - LH Stock was up 2.9%

• Received FDA approval for the nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic for Pfizer's gene therapy to treat Hemophilia B patients.
• Approval signifies a significant advancement in precision medicine and gene therapy, underlining Labcorp's leadership in the field.
• Q1 revenue surpassed forecasts, showing a 4.6% increase driven by organic growth and acquisitions, boosting investor confidence in the company's future prospects.
• Market responded positively to the developments, with investors likely optimistic about Labcorp's sustained success in precision medicine and gene therapy.

15.01.2024 - LH Stock was down 1.1%

• The recent decline in the stock of LH could be attributed to the following factors:
• 1. Lower-than-expected earnings: Labcorp's Q4 earnings were notably lower compared to the same period last year, resulting in a negative EPS. This decline in profitability may have affected investor sentiment and contributed to the bearish market movement.
• 2. Disappointing revenue growth: Although Labcorp reported higher revenue for the fourth quarter and full year compared to the previous year, the growth rate fell short of expectations. This slower revenue growth may have raised concerns among investors about the company's ability to sustain its performance in the future.
• 3. Uncertainty in future earnings: While Labcorp provided guidance for 2024 profit that exceeded Wall Street expectations, the lack of clarity in the earnings forecast could have influenced the bearish market movement. Investors may be cautious about potential challenges or uncertainties that could impact Labcorp's profitability in the coming years.
• 4. Overall market sentiment: The broader market conditions and investor sentiment towards the life sciences sector could have also played a role in Labcorp's stock decline. Factors such as macroeconomic trends, industry competition, and regulatory developments can impact investor confidence and contribute to market fluctuations.

03.06.2023 - LH Stock was down 13.0%

• The bearish movement in LH's stock today could be attributed to the following factors:
• 1. Anticipation of second-quarter financial results: Investors may have been cautious ahead of Labcorp's upcoming financial results announcement. Uncertainty surrounding the company's performance could have led to selling pressure on the stock.
• 2. Market sentiment towards medical research stocks: Despite the potential for growth in the medical research industry, overall market sentiment towards this sector might have been negative today. This negative sentiment could have influenced the bearish movement in LH's stock.
• 3. Lack of positive catalysts: The absence of any specific positive news or developments related to Labcorp may have contributed to the bearish movement. Without any significant catalysts to drive the stock higher, investors may have chosen to sell their positions.
• 4. General market conditions: It's important to consider that broader market conditions and macroeconomic factors can also impact individual stock movements. If the overall market experienced a bearish trend today, it could have influenced LH's stock as well.

20.04.2024 - LH Stock was down 2.6%

• Dr. R. Sanders Williams and Mr. Jean-Luc Bélingard retired from Labcorp's board of directors, which potentially led to investor uncertainty.
• Despite the introduction of a new first-trimester preeclampsia screening test, the market did not respond positively to this development.
• The sale of over $420k in company stock by a Labcorp executive may have sparked concerns about insider sentiment and future company performance.
• The overall bearish movement in Labcorp's stock today could be attributed to a combination of key personnel changes, new product launches, and insider selling.

18.01.2026 - LH Stock was up 5.8%

• Labcorp's target price was raised to $326 by Baird, maintaining an "Outperform" rating, reflecting positive sentiment.
• Labcorp reported strong Q4 and full-year 2025 earnings, with an optimistic 2026 outlook driven by strategic priorities and upbeat profit forecasts.
• JPMorgan adjusted Labcorp's price target to $330, maintaining an "Overweight" rating, following the company's positive Q4 results and 2026 guidance.
• The bullish movement could be attributed to the company's strong financial performance, positive analyst ratings, and strategic growth initiatives, including the launch of an FDA-cleared Alzheimer's blood test.

02.01.2026 - LH Stock was down 1.0%

• Labcorp Holdings recently extended its receivables facility and included a $125 million accordion feature, enhancing financial flexibility. However, this positive development did not significantly influence market activity.
• Thrivent Financial for Lutherans raised its stake in Labcorp Holdings, indicating strong investor confidence, though the stock continued to trend bearishly.
• Speculation about Labcorp Holdings being undervalued, with suggestions of a fair value of $300.06 per share, could be influencing the bearish movement as investors exercise caution.
• Guardant Health's FDA approval for its liquid biopsy for colorectal cancer may have redirected some attention and investments from Labcorp Holdings, resulting in a negative impact on its market performance.

17.01.2026 - LH Stock was down 1.1%

• Despite reporting strong earnings and an optimistic annual profit forecast, Labcorp's stock faced downward pressure.
• The market's reaction may have been influenced by Labcorp's fourth-quarter revenue falling short of projections, despite adjusted earnings per share beating expectations.
• Investor concerns about the company's future revenue performance may have driven the sell-off of Labcorp's shares.
• The discrepancy between revenue and earnings results could have prompted profit-taking by investors, contributing to the bearish trend in Labcorp's stock price.